NCT00361842 - Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Colorectal Neoplasms

Interventions

DRUG

CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection

CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.

Trial Locations (13)

Lombardi Comprehensive Cancer Research Institute, Georgetown University Medical Center, Washington D.C.

Presbyterian Hospital, Charlotte

South Carolina Oncology Association, Columbia

St. Joseph's/Candler Health System Inc., Savannah

NW Oncology & Hematology Associates, Coral Springs

Broward Oncology Associates, Fort Lauderdale

Sarah Cannon Research Institute, Nashville

Gabrail Cancer Center, Canton

California Cancer Center, Greenbrae

Cancer Care Oklahoma, Oklahoma City

Cancer Care Oklahoma, Tulsa

Cross Cancer Institute, Edmonton

Sir Mortimer B. Davis Jewish General Hospital, Montreal